What Side Effects Are Common to Both Drugs Used by Calibrate?

How Calibrate Uses Semaglutide and Tirzepatide

Calibrate is a telehealth metabolic health program that pairs GLP-1 receptor agonist medications with lifestyle coaching. The two medications most commonly prescribed through Calibrate are semaglutide (branded as Wegovy for weight management or Ozempic for type 2 diabetes) and tirzepatide (branded as Mounjaro for diabetes and Zepbound for obesity). Both are injectable, administered once weekly, and both target the GLP-1 receptor system.

Why the Same Receptor Means the Same Side Effects

Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin pathways instead of one 1. The GLP-1 component they share is directly responsible for slowing gastric motility, reducing appetite, and stimulating insulin secretion. Because both drugs hit the same GLP-1 pathway, their gastrointestinal and metabolic side-effect profiles overlap significantly. The additional GIP agonism in tirzepatide does not eliminate GLP-1-driven side effects but may modulate their severity at certain doses.

The Clinical Trials That Mapped These Effects

The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) are the two large Phase III programs that documented side-effect profiles for each drug. STEP-1 enrolled 1,961 adults without diabetes and tested semaglutide 2.4 mg weekly against placebo over 68 weeks 2. SURMOUNT-1 enrolled 2,539 adults without diabetes and tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly against placebo over 72 weeks 3. Comparing adverse-event tables from these two programs reveals the shared side-effect core.

Gastrointestinal Side Effects Shared by Both Drugs

The GI tract is the primary battleground. Nausea, diarrhea, vomiting, and constipation appear in both drug labels, and they are the most frequent reason patients reduce doses or stop treatment.

Nausea

Nausea is the single most reported adverse event for both medications. In STEP-1, 44.2% of participants receiving semaglutide 2.4 mg reported nausea compared with 17.4% on placebo 2. In SURMOUNT-1, nausea rates were 24.6% at the 5 mg dose, 33.3% at 10 mg, and 31.0% at 15 mg of tirzepatide, compared with 9.5% on placebo 3. Tirzepatide's lower nausea rates at comparable weight-loss efficacy may reflect the GIP receptor's gastroprotective signaling, though head-to-head data are limited.

Nausea tends to be worst during the first 2 to 4 weeks of each dose escalation step. It is typically mild to moderate.

Vomiting

Vomiting followed a similar pattern: 24.8% of semaglutide 2.4 mg patients in STEP-1 versus 6.4% on placebo 2. For tirzepatide 15 mg in SURMOUNT-1, vomiting affected 12.2% of participants versus 2.8% on placebo 3. Again, less common with tirzepatide at the highest dose than with semaglutide, but present in both.

Diarrhea

Diarrhea occurred in 30.0% of semaglutide 2.4 mg participants versus 15.6% on placebo in STEP-1 2. In SURMOUNT-1, diarrhea rates ranged from 18.7% to 21.0% across tirzepatide doses, compared with 7.3% for placebo 3. Diarrhea typically resolves faster than nausea and rarely persists beyond the escalation phase.

Constipation

Both drugs slow gut transit, which can swing the opposite direction. Constipation was reported in 24.2% of semaglutide patients (STEP-1) and 11.7% to 17.1% of tirzepatide patients (SURMOUNT-1), versus roughly 6% to 10% in placebo groups 2 3. Patients may experience alternating diarrhea and constipation during the first months of treatment.

Abdominal Pain and Dyspepsia

Abdominal discomfort, often described as bloating, cramping, or upper abdominal pain, appeared in 6% to 11% of participants across both trial programs. Dyspepsia was specifically reported in about 9% of semaglutide users and 5% to 9% of tirzepatide users. Eating smaller, lower-fat meals helps reduce these symptoms 4.

Non-GI Side Effects That Overlap

Not all shared reactions involve the stomach and intestines. Several systemic side effects appear in both drug profiles.

Headache

Headache affected 13.6% of semaglutide 2.4 mg users in STEP-1 and 11% to 13% of tirzepatide users across SURMOUNT-1 dose groups 2 3. Placebo rates were 11% to 12%, suggesting a modest but real drug-related effect. Headaches tend to occur early and diminish with continued use.

Fatigue

Fatigue was reported in approximately 10% to 11% of participants in both programs, compared with 5% to 7% on placebo. This likely relates to reduced caloric intake and rapid metabolic shifts rather than a direct pharmacological effect. Adequate protein intake (at least 1.2 g/kg/day) and hydration may mitigate fatigue during weight loss 5.

Injection-Site Reactions

Because both drugs are subcutaneous injections, localized reactions (redness, swelling, itching, or mild pain at the injection site) occur in 3% to 6% of users of either medication 2 3. Rotating injection sites between the abdomen, thigh, and upper arm reduces this risk.

Dizziness

Dizziness was reported at rates of 5% to 8% in both trial populations. It may relate to hypoglycemia in patients who are concurrently on sulfonylureas or insulin, or to the blood pressure reductions that both drugs produce 6.

Serious Side Effects Shared by Both Drugs

Both semaglutide and tirzepatide carry identical boxed warnings and share several rare but clinically significant risks.

Medullary Thyroid Carcinoma Warning

The FDA requires a boxed warning on both labels regarding thyroid C-cell tumors. GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors in rodents. It is unknown whether semaglutide or tirzepatide causes medullary thyroid carcinoma (MTC) in humans 7. Both drugs are contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Acute Pancreatitis

Pancreatitis has been reported with both drugs at rates under 1%. In STEP-1, acute pancreatitis occurred in 0.2% of semaglutide patients. SURMOUNT-1 reported similar low rates 2 3. Patients should discontinue the medication immediately if persistent, severe abdominal pain develops.

Gallbladder Events

Cholelithiasis (gallstones) and cholecystitis occurred in 1.6% to 2.6% of semaglutide and 0.6% to 1.7% of tirzepatide patients across their respective trials 8. Rapid weight loss is an independent risk factor for gallstone formation, so this risk may partly reflect the weight loss itself rather than a direct drug effect. The American Gastroenterological Association notes that weight loss exceeding 1.5 kg per week raises gallstone risk regardless of the method used.

Hypoglycemia Risk

Neither drug causes frequent hypoglycemia when used alone. The risk increases substantially when either medication is combined with insulin or sulfonylureas. In both trial programs, hypoglycemia requiring assistance was rare (<0.5%), but rates climbed when background diabetes medications were not dose-adjusted 9.

When Side Effects Peak and How Long They Last

Understanding timing is half the battle for patients starting either drug through Calibrate or any prescriber.

The Dose-Escalation Window

Both semaglutide and tirzepatide use a gradual dose-escalation protocol. Semaglutide starts at 0.25 mg weekly and increases every 4 weeks to a target of 2.4 mg. Tirzepatide starts at 2.5 mg and escalates every 4 weeks to 5, 10, or 15 mg. Each step up can trigger a new wave of GI symptoms. The worst period is typically the first 1 to 3 weeks after any dose increase.

The 4-to-8-Week Resolution Rule

A pooled analysis of GLP-1 RA trials found that 60% to 80% of patients experiencing nausea at dose escalation had symptom resolution within 4 to 8 weeks at a stable dose 10. The Endocrine Society's 2023 obesity pharmacotherapy guideline recommends that clinicians counsel patients to expect transient GI symptoms during titration and only consider discontinuation if symptoms persist beyond 8 weeks at a given dose 11.

"The GI side effects of GLP-1 receptor agonists are dose-dependent and self-limiting in the majority of patients," according to the Endocrine Society's 2023 Clinical Practice Guideline on pharmacological treatment of obesity 11.

Strategies That Reduce Shared Side Effects

Both drugs respond to the same mitigation techniques. Eating smaller meals, chewing slowly, and avoiding high-fat or greasy foods reduces nausea and bloating. Staying hydrated prevents constipation and the headaches that dehydration compounds. Taking the injection at bedtime may allow patients to sleep through the worst of the nausea window. If GI symptoms are severe, prescribers may hold the patient at a lower dose for an additional 4 weeks before escalating.

How Side-Effect Severity Compares Between the Two Drugs

Although the side-effect types are the same, their intensity differs.

Tirzepatide May Be Better Tolerated at Equal Efficacy

In the SURMOUNT-1 data, tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks, compared with 14.9% for semaglutide 2.4 mg in STEP-1 at 68 weeks 2 3. Despite greater weight loss, tirzepatide 15 mg had lower nausea (31.0% vs 44.2%), lower vomiting (12.2% vs 24.8%), and comparable diarrhea rates. The SURPASS-2 trial in type 2 diabetes confirmed this pattern when tirzepatide was compared directly to semaglutide 1 mg, showing similar GI event rates but superior glycemic control for tirzepatide 1.

Discontinuation Rates Tell the Same Story

Treatment discontinuation due to adverse events was 7.0% for semaglutide 2.4 mg in STEP-1 and 4.3% to 6.6% across tirzepatide doses in SURMOUNT-1, versus 3.1% to 3.2% for placebo 2 3. GI events accounted for the majority of discontinuations in both programs.

"Both semaglutide and tirzepatide demonstrate acceptable safety profiles for long-term obesity treatment, with gastrointestinal tolerability improving over time," noted the 2023 AGA Clinical Practice Update on obesity pharmacotherapy 12.

What Calibrate Patients Should Monitor

Both drugs require the same baseline and ongoing monitoring regardless of which one is prescribed.

Before Starting Either Drug

A prescriber should evaluate thyroid history (personal or family MTC/MEN 2), gallbladder history, history of pancreatitis, kidney function (both drugs are associated with rare cases of acute kidney injury from dehydration secondary to vomiting/diarrhea), and concurrent diabetes medications that may need dose adjustment 9.

Red-Flag Symptoms That Require Immediate Contact

Stop the medication and contact the prescriber if any of these occur: severe abdominal pain that does not resolve within hours (pancreatitis concern), a visible or palpable neck mass or persistent hoarseness (thyroid concern), signs of an allergic reaction such as facial swelling or difficulty breathing, or persistent vomiting lasting more than 48 hours with inability to keep fluids down (dehydration and acute kidney injury risk) 7.

Ongoing Monitoring Intervals

The Endocrine Society recommends weight, heart rate, and blood pressure checks at each dose escalation visit, plus periodic lipid panels and HbA1c if applicable. Neither drug requires routine calcitonin monitoring in the general population, despite the thyroid boxed warning 11.

Patients enrolled in Calibrate receive regular check-ins with their care team, which can catch emerging side effects before they become serious. The clinical benefit of structured follow-up during GLP-1 therapy is one reason programs like Calibrate pair prescriptions with ongoing clinical support.